Resources

PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).

With Rare Disease Day coming up next weekend, we at BIA are taking time to reflect on our important advocacy and thought leadership in this space, but also on what we hope to achieve in terms of boosting our influence collectively alongside our Charity Partner of the Year.

Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.

It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.

ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).

Brainomix has published a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment.

The Functional Genomics Screening Laboratory, based at the Milner Therapeutics Institute, has won an OBN Award in the category of Most Impactful Industry Collaboration.

GLP-1 collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

The UK’s used nuclear materials will be recycled to create an evergreen supply of new precision cancer medicines, offering hope for patients with previously untreatable cancers.

Oxford-based techbio startup Scripta Therapeutics emerges from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science Enterprises (OSE) and Apollo Health Ventures, with further investment from AlbionVC, YZR Capital, and Parkwalk Advisors, and support from Oxford University Innovation.